Dyadic International, Inc.

NASDAQ:DYAI

Biotechnology

Healthcare
$1.47 +21.49%

+$0.26 today

Market cap
$53.56M
Beta
1.15
P/E (TTM)
-6.9
EPS (TTM)
-$0.20
52W Low $0.65High $1.55

Volume 0.71M

Average 0.31M

DYAI Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Dyadic International, Inc.NASDAQ: DYAI

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 28.7%

Gross margin was 28.7% in Q1 FY2026, up 91.3 pp from a year earlier. On a trailing-twelve-month basis it was 31.3%, down 28.4 pp year over year. Over 3 fiscal years it narrowed by 115.8 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
28.7%+91.9 pp QoQ
Last fiscal yearDec 2025
-88.3%-154.1 pp YoY
LTMMar 2026
31.3%-28.4 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+91.3 pp——
1 year-154.1 pp——
3 years-115.8 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
-88.3%
Year-over-year change
-154.1pp

Gross Margin vs competitors

How DYAI compares with its peers on the latest reported figures

  • DYAI's LTM Mar 2026 gross margin of 31.3% is the lowest of the 4 companies compared; the peer median is 78.7%.
  • Its year-over-year change of -28.4 pp is the lowest of 4, against a peer median of +3.7 pp.
  • Over three fiscal years its change of -115.8 pp compares with a peer median of +45.1 pp.
DYAI Competitors Peer median
Gross Margin for DYAI and competitors
Company Period LTM level YoY 3-year change
ATHEAlterity Therapeutics LimitedFY202597.7% +3.0 pp+4.8 pp
RNXTRenovoRx, Inc.LTM Mar 202678.7% +17.9 pp—
CELUCelularity Inc.LTM Dec 202576.0% +3.7 pp+85.4 pp
DYAIDyadic International, Inc.LTM Mar 202631.3% -28.4 pp-115.8 pp
MAIAMAIA Biotechnology, Inc.FY2025— ——
PYPDPolyPid Ltd.FY2025— ——
VERUVeru Inc.FY2025— ——
ANVSAnnovis Bio, Inc.FY2025— ——
Peer median (excluding DYAI) 78.7%+3.7 pp+45.1 pp

Competitors are the stored peer set for DYAI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.4M2.93M2.9M3.5M1.23M
Cost of Revenue1.94M2.12M1.98M1.19M2.32M
Gross Profit459.39K807.11K922.96K2.3M(1.09M)
Gross Margin19.1%27.5%31.8%65.8%-88.3%
Research & Development8.39M4.5M3.3M2.04M2.15M
Selling, General & Admin6.7M6.42M5.82M6.13M5.76M
Operating Expenses15.19M10.97M9.15M8.2M6.06M
Depreciation & Amortization3.49M038.42K00
EBITDA(11.14M)(10.12M)(8.15M)(5.38M)(6.91M)
EBITDA Margin-463.4%-345.2%-281.3%-154.0%-560.6%
Operating Income(14.73M)(10.17M)(8.23M)(5.9M)(7.15M)
Operating Margin-612.7%-346.9%-283.9%-168.8%-579.9%
Interest Income51.7K180.42K416.69K456.99K284.09K
Interest Expense000427.97K455.9K
Other Income / Expenses1.66M430.42K1.43M91.66K(218.71K)
Income Before Tax(13.07M)(9.74M)(6.8M)(5.81M)(7.36M)
Pre-Tax Margin-543.7%-332.2%-234.4%-166.2%-597.6%
Income Tax Expense00000
Net Income(13.07M)(9.74M)(6.8M)(5.81M)(7.36M)
Net Margin-543.7%-332.2%-234.4%-166.2%-597.6%
EPS (Basic)(0.47)(0.34)(0.24)(0.20)(0.23)
EPS (Diluted)(0.47)(0.34)(0.24)(0.20)(0.23)
Weighted Avg Shares27.84M28.36M28.8M29.32M32.62M
Weighted Avg Shares (Diluted)27.84M28.36M28.8M29.32M32.62M

Dyadic International, Inc.

NASDAQ:DYAI

Intrinsic Alpha fair value

Locked

Current Price

$1.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.